Vasily Kashtalap

Dr. Vasily Kashtalap

Research Institute for Complex Issues of Cardiovascular Diseases

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
DBDaria Borodkina
Daria Borodkina
OAOlga Akbasheva
Olga Akbasheva
OBOlga Barbarash
Olga Barbarash
Determination of the impact of visceral obesity and epicardial adipose tissue thickness on stimulating growth factor levels during hospitalization for myocardial infarction is of potential importance for predicting outcomes and assessing the development of cardiofibrotic changes associated with maladaptive myocardial remodeling. In this study, we aimed to investigate the relationships between epicardial adipose tissue thickness, adipokine profiles, and the stimulating growth factor 2/interleukin-33 signaling system during hospitalization for myocardial infarction, and with the cardiac fibrosis extent 1-year post-MI in patients with visceral obesity. Eighty-eight patients with myocardial infarction were grouped based on their visceral obesity. Serum leptin, adiponectin, stimulating growth factor 2, and interleukin-33 levels were measured on days 1 and 12 and at 1 year. The epicardial adipose tissue widths and the cardiac fibrosis areas were measured on day 12 and at 1 year. Visceral obesity was associated with epicardial adipose tissue thickness increases, adipokine imbalances, elevated leptin levels, and lower adiponectin levels during early hospitalization, and cardiac fibrosis development. Patients without visceral obesity had higher interleukin-33 and stimulating growth factor 2 levels during early hospitalization and lower cardiac fibrosis rates. Epicardial adipose tissue thickness was positively associated with cardiac fibrosis prevalence and interleukin-33 levels and negatively associated with stimulating growth factor 2 levels. The cardiac fibrosis extent was negatively associated with interleukin-33 levels and positively associated with stimulating growth factor 2 levels. Increases in epicardial adipose tissue thickness are associated with cardiac fibrosis development 1-year post-myocardial infarction and are higher in patients with visceral obesity. The metabolic activity of the epicardial adipose tissue is associated with elevated interleukin-33 and reduced stimulating growth factor 2 levels.

14 June 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MYM. V. Yezhov
M. V. Yezhov
SBS. A. Bliznyuk
S. A. Bliznyuk
NTNarek Tmoyan
Narek Tmoyan
TRT. A. Rozhkova
T. A. Rozhkova
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
ТКТ. Ю. Кузнецова
Т. Ю. Кузнецова
Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС)

24 June 2020 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
VKV. N. Karetnikova
V. N. Karetnikova
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
TZT. N. Zvereva
T. N. Zvereva
AKAnastasia Kochergina
Anastasia Kochergina
The management of these patients requires healthcare professionals to have specific knowledge on the characteristics of the viral infection, its clinical signs and symptoms combined with cardiovascular diseases, as well as individual and collective prevention measures. The safety of healthcare professionals and favorable prognosis of patients are of the top priority for the modern healthcare system.The review discusses current challenges associated with the novel coronavirus disease COVID-19 and cardiovascular diseases. The results of few clinical trials and individual case reports have shown the presence of certain problems in treating patients with comorbidity and viral infection. The new data on the drug interactions are reported. Common patterns of typical cardiovascular diseases and COVID-19 are presented. The risk groups with the need for timely diagnosis and intensive cardiac care are identified to prevent adverse outcomes in patients with this comorbidity.

15 January 2017 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ВКВ. Н. Каретникова
В. Н. Каретникова
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
СКС. Н. Косарева
С. Н. Косарева
OBOlga Barbarash
Olga Barbarash
Fibrosis is one of the main components in the progression of most cardiovascular diseases, including coronary heart disease, by causing structural changes in the myocardium and vascular wall. The quantitative and qualitative characteristics of fibrosis of the myocardium are responsible for decreasing its elastic properties, developing diastolic dysfunction, impairing myocardial contractility, developing systolic dysfunction and cardiac arrhythmias, and worsening coronary blood flow in patients with heart failure of different etiologies. The important aspect of studying fibrosis is not only its interpretation as a model of the typical pathological process, but also its consideration as a systemic lesion of various organs and tissues. At the same time, the identification of myocardial fibrosis biomarkers that are available for their determination in circulating blood is of particular interest. Since there was evidence for the role of fibrosis in developing dysfunction of various organs and ensuring the systematicity of most diseases, especially at their development stages, the process of fibrosis came to be regarded as a promising therapeutic target. It is relevant to further investigate myocardial fibrosis, which is aimed at increasing the efficiency of its diagnosis and predicting its course and pathogenetically sound therapy.

8 May 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
MVM. I. Voyevoda
M. I. Voyevoda
GGG. R. Galstyan
G. R. Galstyan
MSMarina Shestakova
Marina Shestakova
SBSergey Boytsov
Sergey Boytsov
GCGalina Chumakova
Galina Chumakova
Предиабет как междисциплинарная проблема: определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений

1 January 2017 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ISI. V. Samorodskaya
I. V. Samorodskaya
OBOlga Barbarash
Olga Barbarash
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
МSМ. А. Starinskaya
М. А. Starinskaya
АНАЛИЗ ПОКАЗАТЕЛЕЙ СМЕРТНОСТИ ОТ ИНФАРКТА МИОКАРДА В РОССИЙСКОЙ ФЕДЕРАЦИИ В 2006 И 2015 ГОДАХ